BPC-157 vs TB-500: What Each Peptide Is and What the Research Shows

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV and an average mass of about 1419.5 Da. Sikiric and colleagues describe it as a partial sequence of body protection compound, a protein they isolated from human gastric juice, and report that the peptide stays stable in human gastric juice.

The mechanistic papers point to blood-vessel signalling. Hsieh and co-workers (Journal of Molecular Medicine, 2017) found that BPC-157 raised VEGFR2 expression in rat ischaemic muscle and in cultured endothelial cells, and activated the VEGFR2-Akt-eNOS pathway. Chang and co-workers (Journal of Applied Physiology, 2011) reported faster outgrowth and migration of rat tendon fibroblasts, with FAK and paxillin phosphorylation rising as the concentration went up. The same group later reported higher growth hormone receptor expression in tendon fibroblasts (Molecules, 2014). Sikiric's group has published a long series on interactions with the nitric oxide system.

Nearly all of this is animal or cell work. A 2025 systematic review in HSS Journal (Vasireddi et al.) screened 544 records on musculoskeletal outcomes and kept 36 studies: 35 preclinical and 1 clinical. The clinical paper was a retrospective knee-pain series of 12 patients, and the reviewers found no clinical safety data. No regulator has approved BPC-157, and the 2026 WADA Prohibited List names it under S0, non-approved substances.

Thymosin beta-4 is a 43-amino-acid protein of about 5 kDa and the main G-actin sequestering peptide in mammalian cells. It holds actin monomers and so sets how fast filaments form, which governs how a cell changes shape and moves. Its actin-binding motif is LKKTETQ, residues 17 to 23.

Anti-doping chemists who analysed TB-500 products (Esposito et al. and Ho et al., Drug Testing and Analysis, 2012) identified the active ingredient as Ac-LKKTETQ: that motif with an acetylated N-terminus, seven residues, about 889 Da. Philp and colleagues (FASEB Journal, 2003) showed why the fragment draws interest. In endothelial migration and aortic-ring sprouting assays, the seven-residue motif matched full-length thymosin beta-4 at about 50 nM, and peptides missing any part of the motif had no activity.

The headline thymosin beta-4 findings come from the full protein. Bock-Marquette and colleagues (Nature, 2004) reported that it formed a complex with PINCH and integrin-linked kinase, activated Akt and improved cardiac function after coronary ligation in mice. Full-length thymosin beta-4 has also reached human trials as an ophthalmic solution (RGN-259). In the SEER-1 phase 3 trial in neurotrophic keratopathy, 6 of 10 treated patients and 1 of 8 on placebo showed complete healing at four weeks (p = 0.0656). None of that clinical work used TB-500. WADA lists thymosin beta-4 and its derivatives, TB-500 included, under S2.

One group has. Biçer and colleagues (Joint Diseases and Related Surgery, July 2026) cut and repaired the Achilles tendon in 32 rats and split them into four groups of eight: control, BPC-157, TB-500, and both peptides. After four weeks of treatment, only the TB-500 group showed a significantly higher maximum load to failure. The TB-500 group and the combination group scored better than controls on Movin histology; the BPC-157 group moved the same way without reaching significance. The combination gave no added benefit over either peptide alone. The authors suggest the two may converge on shared downstream pathways and call that hypothesis untested.

Eight animals per arm make this an exploratory result. For a study designer it argues for single-agent arms: a combination arm on its own cannot show which peptide produced an effect, and in this study the second peptide added nothing measurable.

If you hold a blend vial, the practical question is whether the two peptides stay stable together. We found no published data on the chemical stability of the two peptides in one solution, so any storage period quoted for a blend is an assumption until someone measures it.

The reconstitution arithmetic treats each peptide as its own solute in a shared volume:

The masses differ enough that one mass spectrum settles identity: about 1419.5 Da for BPC-157, about 889 Da for Ac-LKKTETQ and about 5 kDa for full-length thymosin beta-4. Product listings do not always say which molecule they mean by TB-500, so check the observed mass on the certificate against the molecule you expect.

An independent laboratory assays every Encodex lot, by HPLC for purity and by mass spectrometry for identity. The certificate for the lot printed on your vial is available on request, and you can enter that lot number on the /verify page.